# AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

> **NCT07668401** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 400 (estimated)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** Zenagamtide
- **DRUG:** Placebo ( matched to Zenagamtide)

## Key facts

- **NCT ID:** NCT07668401
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-07
- **Primary completion:** 2029-01-11
- **Final completion:** 2029-01-11
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668401, "AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*